Foundation Medicine Workshop

What’s Next in the Future of Precision Oncology

Featuring voices from the industry – in partnership with Foundation Medicine

FMI_vertical-slate[2][3][1][2][1][3]

Foundation Medicine Workshop

Wednesday 6th September 2023

9:00 am Morning Registration & Networking

10:00 am Opening Welcome Remarks & Market Trends (Voices from the Industry)

  • Troy Schurr Chief BioPharma Business Officer, Foundation Medicine

10:30 am Finding Success in Companion Diagnostics: How to Select the Right Partner to Overcome Key Therapy Development Challenges

  • Matthew Cooke Director, Business Development, CDx Strategy & Partnering, Foundation Medicine
  • Agnes Jung VP, Head of Clinical Development & Operations, Bridge Biotherapeutics Inc
  • Michael Teufel Executive Director - Oncology, Boehringer Ingelheim
  • Ian Silverman Associate Director, Bioinformatics, Repare Therapeutics

Synopsis

  • Share key challenges in precision oncology therapy development and discuss potential diagnostic solutions 
  • Discuss how the “right partner” can address challenges and improve the probability of success from discovery to approval  
  • Identify trends anticipated to advance precision oncology in key markets 

11:15 am Networking Break

11:30 am Activity Breakout Tables Aligned by Interest

12:00 pm Defining Fit For Purpose Real-World Evidence for Supporting Companion Diagnostics Approvals: Creating a Checklist for Evaluating Real-World Data

Synopsis

  • Trends in the use of RWD/E for regulatory approvals in oncology and potential CDx use cases
  • Foundation Medicine’s Fit-For-Purpose RWE Framework for CDx and RWD/E for CDx Checklist for evaluating RWD/E
  • Case Study: Approval of FoundationOne®CDx to be used as a companion diagnostic inclusive of post-approval study leveraging the Flatiron Health – Foundation Medicine Clinico-Genomic Database (CGDB)

12:20 pm Fireside Chat: Monitoring

  • Geoff Oxnard Senior Vice President, Head of Clinical Development, Foundation Medicine
  • Brenton Mar Senior Vice President and Head, Clinical Development, Relay Therapeutics

Synopsis

  • What to look for in an assay when evaluating ctDNA dynamics in clinical programs
  • When and why it makes sense to incorporate monitoring into a program
  • Discussing the value and importance of Tumor Fraction
  • The benefits of using monitoring to look at response to therapy and resistance mutations

12:50 pm Q&A Closing Remarks

  • Troy Schurr Chief BioPharma Business Officer, Foundation Medicine

1:00 pm Networking Lunch Break

REGISTER INTEREST HERE